Login / Signup

Biosimilars in Malaysia: Regulatory Framework, Approved Products, and Adverse Effects.

Noraisyah Mohd SaniZoriah AzizAdeeba Kamarulzaman
Published in: Therapeutic innovation & regulatory science (2020)
Malaysia follows a stringent regulatory pathway for the approval of biosimilars enacted by well-established regulatory agencies to maintain the quality, efficacy and safety of biosimilars. Introducing biosimilars to the Malaysian market would improve patients' accessibility to biologic therapies.
Keyphrases
  • end stage renal disease
  • transcription factor
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • rheumatoid arthritis
  • peritoneal dialysis
  • prognostic factors
  • health insurance
  • drug administration